A Phase 1/2 Study of Mirdametinib and Vinblastine for Newly Diagnosed or Previously Untreated Patients With Pediatric Low-grade Glioma and Activation of the MAPK Pathway

This is a 3-part open-label study (feasibility phase, treatment phase and follow-up phase) of orally administered mirdametinib in combination with intravenous vinblastine chemotherapy in patients with PLGG with activation of MAPK pathway.
Feasibility Phase:
The maximum tolerated/recommended phase 2 dose (MTD/RP2D) of the mirdametinib plus vinblastine combination will be assessed using a modified Rolling-6 design.
Treatment Phase:
Patients will receive mirdametinib twice daily (continuously) at a fixed dose (2mg/m2 po BID up to 4 mg BID) for a total of 13 cycles (28 days cycle). Weekly intravenous vinblastine at MTD will be given for a total of 17 cycles. If adverse events occur, two dose reductions are allowed.
Follow-up Phase:
Following the end of treatment, patients will be scheduled for a follow-up visit every 6 months for 36 months to evaluate PFS, TTP and OS.

开始日期2025-01-01

申办/合作机构-

NCT06502171 / Not yet recruiting临床1期IIT

A Phase 1/1b/2 Study of Cabozantinib in Combination with Selumetinib for Plexiform Neurofibroma in Adults and Adolescents with Neurofibromatosis Type 1

Based on the clinical activity of both selumetinib and cabozantinib as monotherapies in clinical trials, the demonstrated activity of these agents in reduced doses in preclinical studies, and the non-overlapping toxicity profiles, the study will assess the tolerability and efficacy of selumetinib and cabozantinib in combination in participants with NF1 ≥16 years old with progressive and/or symptomatic PN in a phase 1/1b/2 clinical trial.
Trial Design Phase 1 This will be an open label, dose escalation phase. Dose level escalation will be determined by a rolling six design. In this design, up to 6 participants can be enrolled at a given dose level and then evaluated for dose limiting toxicity (DLT) within the DLT window. The DLT window is defined as 16 weeks in this study based on the long half-life of cabozantinib and the desire to have maximum confidence about long-term tolerability of the combination prior to proceeding to the next dose level.
Phase 1b Once the recommended phase 2 dose has been determined in phase 1, an expanded cohort of 12 participants will be enrolled in phase 1b portion of the study.
Phase 2 This will be an open label, single-arm phase using the recommended phase 2 dose.

开始日期2025-01-01

申办/合作机构

The University of Alabama at Birmingham

[+2]

100 项与 MEK1 x MEK2 相关的临床结果

登录后查看更多信息

100 项与 MEK1 x MEK2 相关的转化医学

登录后查看更多信息

0 项与 MEK1 x MEK2 相关的专利（医药）

登录后查看更多信息

551

项与 MEK1 x MEK2 相关的文献（医药）

2024-05-10·Alternative therapies in health and medicine

The Efficacy of Recombinant Human Type III Collagen in the Treatment of Atrophic Scars and Its Impact on p38 MAPK Signaling Pathway Proteins.

Article

作者: Chen, Changhan ; Xu, Genyan ; Ke, Youhui ; Ke, Chen ; Yan, Jun ; Zhang, Ruobing ; Shao, Wenhui ; Zhang, Qianyue

ObjectiveTo investigate the effects of recombinant human type III collagen on atrophic scars and its impact on the p38 mitogen-activated protein kinase (p38MAPK) signaling pathway.MethodsA total of 94 patients with atrophic scars admitted to our hospital from March 2020 to October 2022 were selected as subjects and evenly divided into a control group and an observation group. The control group (n = 47) received carbon dioxide fractional laser treatment, while the observation group (n = 47) was treated with recombinant human type III collagen dressings in addition to the laser treatment. Clinical efficacy, scar conditions, skin physiological parameters, serum levels of p38MAPK pathway-related proteins, and inflammatory markers were compared between the two groups.ResultsThe overall effective rate in the observation group was 95.74%, significantly higher than 74.47% in the control group (P < .05). Before treatment, there was no significant difference in Vancouver Scar Scale (VSS) scores, stratum corneum hydration, and transepidermal water loss between the two groups (P > .05). After treatment, the VSS score in the observation group was significantly lower than in the control group (P < .05). Similarly, prior to treatment, there were no significant differences in serum levels of mitogen-activated protein kinase 1 (MEK1), mitogen-activated protein kinase 2 (MEK2), extracellular signal-regulated kinase 1 (ERK1), and extracellular signal-regulated kinase 2 (ERK2), interleukin-10 (IL-10) and tumor necrosis factor-alpha (TNF-α) between the two groups (P > .05). After treatment, levels of MEK1, MEK2, ERK1, ERK2, IL-10, and TNF-α in the observation group were significantly lower than those in the control group (P < .05).ConclusionRecombinant human type III collagen significantly improves the treatment of atrophic scars, effectively ameliorating scar conditions and skin physiology. It also regulates the p38MAPK signaling pathway and reduces inflammation.

2024-04-01·Journal of Ethnopharmacology

Uncovering the pharmacological mechanism of Shou Tai Wan on recurrent spontaneous abortion: A integrated pharmacology strategy-based research

Article

作者: Yang, Kailin ; Zhang, Guomin ; Wu, Lingyu ; Li, Yuwei ; Zeng, Liuting ; Wang, Guiyun ; Wu, Xiaolan ; Huang, Shanshan ; Liu, Huiping ; Yu, Rong ; Xiang, Wang ; Bao, Tingting

ETHNOPHARMACOLOGICAL RELEVANCEShou Tai Wan (STW), a traditional Chinese medicine formula, has been historically used for the treatment of recurrent spontaneous abortion (RSA). Despite its long-standing usage, the exact mechanism underlying the therapeutic effects of STW remains unclear in the existing literature.AIMS OF THIS STUDYTo explore the Pharmacological Mechanism of STW on RSA.METHODSA network pharmacological methodology was utilized to predict the active compounds and potential targets of STW, collect the RSA targets and other human proteins of STW, and analyze the STW related networks. The animal experiments were also performed to validate the effect of STW on RSA.RESULTSThe results of network analysis showed that STW may regulate PI3K/AKT, MAPK, FoxO signaling pathways and so on. Animal experiment established the RSA model with CBA/J × DBA/2 mice. It was found that STW can reduce the embryo absorption rate of RSA group (p < 0.05) and balance the expression of Th 1/Th2 type cytokines compared with the model group. After 14 days of administration, the decidual and placental tissues were taken and the CD4⁺ T cells were isolated, and the phosphorylation level of signaling pathway was detected by Springbio720 antibody microarray. This experiment found that STW can significantly up-regulate the phosphorylation levels of STAT3 and STAT6 proteins in the STAT signaling pathway, and down-regulating the phosphorylation level of STAT1 protein. STW also significantly up-regulated the phosphorylation levels of Raf1, A-Raf, Ask1, Mek1, Mek2, JKK1, ERK1, ERK2, c-fos, c-Jun and CREB proteins in the MAPK signaling pathway, and down-regulate the phosphorylation levels of MEK6 and IKKb proteins. Compared with the RSA group, the STW group increased the expression levels of ERK1/2 mRNA and proteins and p-ERK1/2 proteins, and there was a statistical difference (p < 0.05). This is consistent with the chip results.CONCLUSIONSTW may achieve therapeutic effects by interfering with the signaling pathways, biological processes and targets discovered in this study. It provides a new perspective for revealing the immunological mechanism of STW in the treatment of RSA, and also provides a theoretical basis for the clinical use of STW in the treatment of RSA.

2024-03-01·Molecular & Cellular Proteomics

The Quantitative Biotinylproteomics Studies Reveal a WInd-Related Kinase 1 (Raf-Like Kinase 36) Functioning as an Early Signaling Component in Wind-Induced Thigmomorphogenesis and Gravitropism

Article

作者: Ren, Jia ; Burlingame, Al ; Li, Ning ; Wang, Zhiyong ; Yu, Weichuan ; Leung, Manhin ; Wang, Kai ; Lu, Yinglin ; Yang, Nan ; Xu, Shouling ; An, Yuxing ; Dai, Shuaijian

Wind is one of the most prevalent environmental forces entraining plants to develop various mechano-responses, collectively called thigmomorphogenesis. Largely unknown is how plants transduce these versatile wind force signals downstream to nuclear events and to the development of thigmomorphogenic phenotype or anemotropic response. To identify molecular components at the early steps of the wind force signaling, two mechanical signaling-related phosphoproteins, identified from our previous phosphoproteomic study of Arabidopsis touch response, mitogen-activated protein kinase kinase 1 (MKK1) and 2 (MKK2), were selected for performing in planta TurboID (ID)-based quantitative proximity-labeling (PL) proteomics. This quantitative biotinylproteomics was separately performed on MKK1-ID and MKK2-ID transgenic plants, respectively, using the genetically engineered TurboID biotin ligase expression transgenics as a universal control. This unique PTM proteomics successfully identified 11 and 71 MKK1 and MKK2 putative interactors, respectively. Biotin occupancy ratio (BOR) was found to be an alternative parameter to measure the extent of proximity and specificity between the proximal target proteins and the bait fusion protein. Bioinformatics analysis of these biotinylprotein data also found that TurboID biotin ligase favorably labels the loop region of target proteins. A WInd-Related Kinase 1 (WIRK1), previously known as rapidly accelerated fibrosarcoma (Raf)-like kinase 36 (RAF36), was found to be a putative common interactor for both MKK1 and MKK2 and preferentially interacts with MKK2. Further molecular biology studies of the Arabidopsis RAF36 kinase found that it plays a role in wind regulation of the touch-responsive TCH3 and CML38 gene expression and the phosphorylation of a touch-regulated PATL3 phosphoprotein. Measurement of leaf morphology and shoot gravitropic response of wirk1 (raf36) mutant revealed that the WIRK1 gene is involved in both wind-triggered rosette thigmomorphogenesis and gravitropism of Arabidopsis stems, suggesting that the WIRK1 (RAF36) protein probably functioning upstream of both MKK1 and MKK2 and that it may serve as the crosstalk point among multiple mechano-signal transduction pathways mediating both wind mechano-response and gravitropism.

项与 MEK1 x MEK2 相关的新闻（医药）

2024-10-26

·精准药物

一文解析MAPK 通路

MAPK（丝裂原活化蛋白激酶）通路是细胞内一种重要的信号传导途径，广泛参与调控细胞生长、分化、死亡、应激反应等多种生物学过程。MAPK通路对于细胞应对外界环境变化具有核心作用，涉及到多种疾病的发生发展，包括癌症、炎症性疾病等。一、MAPK通路的组成 MAPK通路主要由三类蛋白激酶组成，它们按照特定的顺序激活： 1.MAPKKK（MAPK激酶激酶）：最上游的激酶，响应信号分子的刺激。 2.MAPKK（MAPK激酶）：由MAPKKK激活，进一步放大信号。 3.MAPK：最终的执行者，被MAPKK激活后，转移到细胞核内，通过磷酸化特定的基因调控蛋白，影响基因表达。图：MAPK通路的基本组成（来自Targeting the Raf-MEK-ERK mitogen-activated protein kinase cascade for the treatment of cancer.）二、MAPK通路的主要分支 MAPK通路可以分为几个主要分支，每个分支由不同的MAPK蛋白构成，主要包括：ERK通路，JNK通路和p38 MAPK通路。 1. ERK通路（Extracellular signal-Regulated Kinases） ERK通路，也称为经典的MAPK通路，主要响应生长因子和一些其他刺激。它通常与细胞增殖和分化过程相关联。主要组成： ●上游激酶：包括Ras小GTPase，它激活RAF激酶（如BRAF）。 ●中间级激酶：RAF激活MEK1和MEK2（MAPK/ERK激酶）。 ●下游激酶：MEK激酶进一步激活ERK1和ERK2。生物学功能： ●细胞增殖：ERK通路的激活促进细胞周期蛋白的表达，推动细胞周期进程。 ●细胞分化：在某些细胞类型中，ERK激活是细胞分化必需的。 ●生存信号：ERK可以激活抗凋亡蛋白，如Bcl-2，帮助细胞逃避程序性细胞死亡。 MAPK/Erk 信号级联放大通过生长和分化中涉及的各种不同受体进行激活，包括受体酪氨酸激酶 (RTKs)、整合素以及离子通道。由不同的刺激物激活的级联反应的特定组分差异较大，但通路的结构通常包含一组对接蛋白（Shc、GRB2、Crk 等），它们将受体连接到一个鸟苷酸交换因子上（SOS、C3G 等），信号则转导至小分子 GTP 结合蛋白 (Ras，Rap1)，后者再激活级联中的核心单位，包括一个 MAPKKK (Raf)、一个 MAPKK (MEK1/2) 和 MAPK (Erk)。激活的 Erk 二聚物可在胞质中调控靶蛋白，也可转运入胞核，在核内磷酸化多种调控基因表达的转录因子。图：生长和分化中的 MAPK/Erk（来自Cell signaling） 2. JNK通路（c-Jun N-terminal Kinases） JNK通路，也称为应激激活蛋白激酶通路，主要响应应激信号，如紫外线照射、热休克和炎症因子。主要组成： ●上游激酶：包括MKK4和MKK7。 ●下游激酶：它们激活JNK1、JNK2和JNK3。生物学功能： ●细胞应激反应：JNK通路在细胞对环境应激做出反应中发挥关键作用。 ●调节细胞死亡：JNK的活化通常与细胞凋亡相关，尤其是在病理条件下。 ●炎症反应：JNK能够调节多种炎症细胞因子的表达。应激活化蛋白激酶 (SAPK)/Jun 氨基末端激酶 (JNK) 是 MAPK 家族的成员，可由各种不同环境应激、炎症细胞因子、生长因子以及 GPCR 激动剂激活。应激反应信号经 Rho 家族（Rac、Rho、cdc42）的小分子 GTP 酶传递到这个级联。和其他 MAPK 一样，膜近端激酶是一个 MAPKKK（通常为 MEKK1–4），或是混合性谱系激酶（MLK）中一员，能磷酸化并激活 MKK4 (SEK) 或 MKK7（即 SAPK/JNK 激酶）。此外， MKK4/7 能由生发中心激酶 (GCK) 家族成员以独立于 GTP 酶的方式激活。SAPK/JNK 转运入胞核后可调节多种转录因子的活性。图：SAPK/JNK信号级联放大（来自Cell signaling） 3. p38 MAPK通路 p38 MAPK通路同样响应应激信号，包括细胞因子和环境应激，常与细胞生存和炎症反应相关。主要组成： ●上游激酶：包括MKK3、MKK4和MKK6。 ●下游激酶：p38 MAPK有四个不同的同源体：p38α、p38β、p38γ和p38δ。生物学功能： ●炎症反应：p38 MAPK是许多炎症介质表达的调节者，对免疫细胞的活化起重要作用。 ●细胞周期调控：p38在某些情况下可以抑制细胞周期的进程，从而影响细胞增殖。 ●细胞分化：特别是在骨骼肌细胞和神经细胞的分化中，p38 MAPK的激活对某些分化途径至关重要。 p38 MAPK（α、β、γ 和 δ）是 MAPK 家族的成员，各种环境应激和炎症细胞因子均可将其激活。对于其他 MAPK 级联，膜近端组分是一个 MAPKKK，其为典型的 MEKK 或混合性谱系激酶 (MLK)。MAPKKK 磷酸化并激活 MKK3/6，后者即是 p38 MAPK 激酶。MKK3/6 也可在凋亡因素的刺激下直接由 ASK1 激活。p38 MAPK 参与调节 HSP27、MAPKAPK-2 (MK2)、MAPKAPK-3 (MK3) 和其他几种转录因子，包括 ATF-2、Stat1、Max/Myc 复合体、MEF-2 和 Elk-1，而 CREB 通过激活 MSK1 间接调控。图：p38 MAPK信号转导相互作用通路（来自Cell signaling）三、MAPK通路的激活机制 MAPK通路通常是通过细胞表面的受体如受体酪氨酸激酶（RTKs）或G蛋白偶联受体（GPCRs）接收信号，触发一系列下游事件： 1.受体激活：受到外界信号分子（如生长因子）的结合后，受体自身活化或聚合，激活与其相连的适配蛋白。 2.Ras蛋白的激活：在ERK通路中，适配蛋白进一步激活小G蛋白Ras。 3.MAPKKK的激活：Ras激活RAF家族蛋白（MAPKKK的一种），后者激活MEK（MAPKK）。 4.MAPK的激活：MEK进一步激活ERK，ERK磷酸化核内的靶蛋白，如转录因子，从而改变基因表达。四、MAPK通路的生理与病理意义 MAPK通路在维持正常细胞功能和发展中起着关键作用，但当这些通路异常激活或抑制时，可能导致多种疾病的发生： ●癌症 MAPK通路的持续激活常见于多种肿瘤，促进肿瘤细胞的增殖和存活。 MAPK信号通路与细胞增殖和分化密切相关。在许多恶性肿瘤中发现MAPK信号的持续激活。细胞增殖在很大程度上有助于肿瘤发生。肿瘤转移和侵袭是致命原因。在哺乳动物MAPK通路中，ERK通路是研究最充分的，在大约三分之一的人类癌症中失调。 ERK1/2通路在肿瘤细胞的增殖、分化、转移和侵袭中起重要作用。温等人发现乙型肝炎病毒x蛋白通过p38/MAPK通路使p53基因失活，从而诱导原发性肝癌（PLC）。Kim MS等人证明，p38 MAPK是Ras诱导的乳腺癌细胞侵袭和转移的关键信号分子。许多研究表明，p38 MAPK通路在细胞外刺激产生的MMP（基质金属蛋白酶）中发挥重要的调节功能。MMP是一种与肿瘤侵袭和迁移密切相关的蛋白水解酶。此外，p38 MAPK通路促进维持肿瘤细胞生长所必需的肿瘤血管生成。癌症经常暴露于各种压力条件下，例如缺氧和炎症。许多MAPK通路都参与应激信号传导。因此，一些激酶在癌症中被应激激活，以响应炎症、DNA 损伤和细胞凋亡。缺氧状态在实体瘤中广泛存在。缺氧信号刺激MKP-1的激活。MKP-1 进一步激活 SAPK/JNK，从而激活 c-Jun。活性 c-Jun 促进多个下游基因转录，这对癌细胞的增殖和存活很重要。 MAPK信号转导的畸变会影响大多数致癌过程，对癌症的发展和进展至关重要。大多数癌症相关病变，如受体酪氨酸激酶的过表达、受体酪氨酸激酶的激活突变、激活配体的持续自分泌或旁分泌产生、Ras 突变和 B-Raf 突变导致 ERK 信号转导的组成型激活。据报道，c-Jun 的 JNK 活性和磷酸化在 Ras 诱导的肿瘤发生中起关键作用。 ●炎症性疾病在炎症性疾病中，MAPK通路通过影响细胞因子、生长因子和应激反应等因素的表达和活性，起到了至关重要的调控作用。 MAPK通路参与调控包括肿瘤坏死因子α（TNF-α）、白细胞介素（如IL-1, IL-6）等多种炎症性细胞因子的产生。这些细胞因子是炎症反应中的关键介质，能够激活更多的免疫细胞和促进炎症反应的发展。MAPK通路通过调节各种趋化因子和黏附分子的表达，影响免疫细胞（如巨噬细胞、T细胞）的活化、迁移和入侵到炎症部位。在炎症和其他应激条件下，JNK和p38 MAPK的激活促进细胞应对损伤和恢复平衡。由于MAPK通路在炎症反应中的核心角色，研究者开发了多种针对该路径的抑制剂，以治疗如类风湿性关节炎、银屑病等炎症性疾病。例如，p38 MAPK抑制剂已被证明可以减轻炎症反应，通过减少炎症性细胞因子的产生。 ●神经退行性疾病在神经退行性疾病的研究中，MAPK通路显示出其在神经保护和神经损伤中的双重作用，这些疾病包括阿尔茨海默病（AD）、帕金森病（PD）、亨廷顿病（HD）和肌萎缩侧索硬化症（ALS）等。 AD中，异常的tau蛋白磷酸化与MAPK通路的过度活化有关。特别是JNK和p38 MAPK在tau磷酸化和神经纤维缠结的形成中起着重要作用。PD中，JNK和p38 MAPK的活化与多巴胺神经元的死亡相关。MAPK通路参与了氧化应激和炎症反应的调控，这些都是PD的关键病理过程。在HD中，JNK的激活与疾病相关的神经毒性密切相关。JNK抑制剂显示出在预防神经退行方面的潜力。五、MAPK通路的治疗应用由于MAPK通路在多种疾病中的核心作用，该通路的组分成为了药物开发的重要靶点。目前已有多种针对MAPK通路的抑制剂被开发用于治疗特定类型的癌症（如BRAF抑制剂在黑色素瘤中的应用）和其他疾病。此外，针对JNK和p38 MAPK的抑制剂也在被研究中，以期治疗炎症和神经退行性疾病。六、总结 MAPK通路是一条复杂的信号传导途径，涉及到多种生理和病理过程。对其深入研究不仅有助于我们理解细胞如何响应外界信号并调控各种细胞功能，还可以为疾病的预防和治疗提供新的策略。随着研究的深入，未来可能会发现更多的关于这一信号通路的调控机制和治疗潜力。声明：发表/转载本文仅仅是出于传播信息的需要，并不意味着代表本公众号观点或证实其内容的真实性。据此内容作出的任何判断，后果自负。若有侵权，告知必删！长按关注本公众号粉丝群/投稿/授权/广告等请联系公众号助手觉得本文好看，请点这里↓

2024-09-12

·drugs

Ingredient in Hair Dye Led to Woman's Vision Loss

THURSDAY, Sept. 12, 2024 -- An ingredient in the hair dye a French woman used caused her to develop a vision-robbing retinopathy , researchers report. When she switched to a dye without these ingredients, called aromatic amines, her vision troubles resolved, according to a team led by Dr. Nicolas Chirpaz , an ophthalmologist at Edouard Herriot Hospital, in Lyon. Such cases could be rare, the researchers said, but spreading awareness of the danger "may allow prompt consideration to remove exposure to such hair dye" so eyes aren't permanently damaged, Chirpaz and colleagues said. They published their case report Sept. 12 in the journal JAMA Ophthalmology . As the French team noted, this isn't the first time hair dye has been linked to retinopathy: Three prior cases were reported in 2022 among "middle-aged women following exposure to hair dyes containing aromatic amines." In the latest case, a 61-year-old woman with no prior history of vision trouble came to doctors with progressively blurry vision in both eyes "a few days after dyeing her hair with hair dye containing aromatic amines," Chirpaz' group said. The aromatic amine in the dye used in this case was para-phenylenediamine. Upon examination, the woman was found to have multiple retinal detachments that resembled the damage that can occur in retinopathies that are tied to certain enzymes found in the eye, called MEK1 or MEK2. The woman's eyes also displayed an unhealthy "thickening of the neurosensory retina," the French team found. Tests were conducted to rule out a host of possible causes, including infections and even cancer. In the end, retinal damage caused by the ingredient in hair dye was "diagnosed based on the temporal association between symptoms and hair dye exposure," the team said. The woman soon switched her brand of hair dye, and her vision returned to 20/20 within a month. "Four years later, the patient reported using aromatic amines–free hair dye and has not experienced any recurrence," the study authors said. Chirpaz' team believes that aromatic amine chemicals such as para-phenylenediamine "disrupt" a neurochemical pathway that's essential to the health of what are known as retinal pigment epithelial cells. Cases of "retinopathy associated with the use of hair dye aromatic amines [RAHDAA]" remain rare, but doctors should be on the alert to the possibility when people show up with any retinopathy that doesn't have an easy explanation, the French team said. Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.

临床结果

2024-09-04

·BioSpace

Recursion Reports Thin Mid-Stage Efficacy Data for Rare Brain Disease Therapy

iStock, Nomadsoul1 Recursion’s oral drug candidate for cerebral cavernous malformation showed no improvements in patient- or physician-reported outcomes at 12 months. The biotech will engage with the FDA to determine the need for an additional study. Recursion on Tuesday released topline data from its Phase II SYCAMORE trial, showing that its drug candidate REC-994 is largely safe to use in patients with cerebral cavernous malformation—though its efficacy pro much to be desired. After 12 months of treatment, both 200-mg and 400-mg doses of REC-994 showed similar adverse event profiles to placebo, indicating that the investigational treatment is largely safe and tolerable for patients with cerebral cavernous malformation (CCM). However, SYCAMORE’s efficacy data were less promising. Magnetic resonance imaging showed a “trend toward reduced lesion volume” in patients who were given the higher, 400-mg dose of REC-994, compared with placebo. These trends improved over time, though Recursion reported no improvements in patient- or physician-reported outcomes at 12 months. Recursion Chief R&D and Commercial Officer Najat Khan in a statement said the biotech is “encouraged” by these findings, which make REC-994 “the first investigational therapy to demonstrate safety” in CCM, while also demonstrating “promising trends in exploratory efficacy endpoints.” “These results provide critical insights that will inform our next study design, including exploring study duration, higher doses, and a larger cohort of patients,” Khan said, noting that Tuesday’s readout “represents an early proof-of-platform milestone” for the biotech. Recursion is seeking a meeting with the FDA “as soon as practical” to determine the way forward for REC-994, including an additional clinical trial, according to the company. The biotech will also present findings from SYCAMORE at an upcoming scientific congress and will submit them for publication in a peer-reviewed journal. CCM is a rare neurovascular disease characterized by malformations of the spinal cord and the brain, often involving abnormally enlarged capillary cavities. The condition affects around 360,000 symptomatic patients, who are at heightened risk of seizures, headaches and progressive neurological deficits, as well as potentially fatal hemorrhagic strokes. There are currently no pharmacologic treatments for CCM. REC-994, an orally available small molecule superoxide scavenger, was discovered using Recursion’s AI-powered drug discovery platform, which leverages “one of the world’s largest proprietary biological and chemical datasets,” according to the biotech’s website . The platform then makes use of machine-learning algorithms to produce an extensive searchable list of interactions from this database. Recursion is also developing REC-2282, another orally available drug candidate that can penetrate the central nervous system, for the treatment of NF2-mutated meningiomas, and REC-4481, a non-ATP-competitive blocker of MEK1 and MEK 2 for familial adenomatous polyposis.

临床2期临床结果